Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: Sensitivity analysis of randomized trials

2014 ◽  
Vol 40 (7) ◽  
pp. 847-856 ◽  
Author(s):  
Emilio Bria ◽  
Luisa Carbognin ◽  
Jenny Furlanetto ◽  
Sara Pilotto ◽  
Maria Bonomi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Sensitivity Analysis ◽  
Advanced Breast Cancer ◽  
Randomized Trials ◽  
Pathological Complete Response ◽  
Locally Advanced Breast Cancer ◽  
Locally Advanced ◽  
Complete Response ◽  
Advanced Breast

scholarly journals CAIX is a predictor of pathological complete response and is associated with higher survival in locally advanced breast cancer submitted to neoadjuvant chemotherapy

BMC Cancer ◽  
2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Wilson Eduardo Furlan Matos Alves ◽  
Murilo Bonatelli ◽  
Rozany Dufloth ◽  
Lígia Maria Kerr ◽  
Guilherme Freire Angotti Carrara ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Advanced Breast Cancer ◽  
Pathological Complete Response ◽  
Locally Advanced Breast Cancer ◽  
Locally Advanced ◽  
Complete Response ◽  
Advanced Breast ◽  
Metabolic Reprogramming ◽  
Caix Expression

Abstract Background Locally advanced breast cancer often undergoes neoadjuvant chemotherapy (NAC), which allows in vivo evaluation of the therapeutic response. The determination of the pathological complete response (pCR) is one way to evaluate the response to neoadjuvant chemotherapy. However, the rate of pCR differs significantly between molecular subtypes and the cause is not yet determined. Recently, the metabolic reprogramming of cancer cells and its implications for tumor growth and dissemination has gained increasing prominence and could contribute to a better understanding of NAC. Thus, this study proposed to evaluate the expression of metabolism-related proteins and its association with pCR and survival rates. Methods The expression of monocarboxylate transporters 1 and 4 (MCT1 and MCT4, respectively), cluster of differentiation 147 (CD147), glucose transporter-1 (GLUT1) and carbonic anhydrase IX (CAIX) was analyzed in 196 locally advanced breast cancer samples prior to NAC. The results were associated with clinical-pathological characteristics, occurrence of pCR, disease-free survival (DFS), disease-specific survival (DSS) and overall survival (OS). Results The occurrence of pCR was higher in the group of patients whith tumors expressing GLUT1 and CAIX than in the group without expression (27.8% versus 13.1%, p = 0.030 and 46.2% versus 13.5%, p = 0.007, respectively). Together with regional lymph nodes staging and mitotic staging, CAIX expression was considered an independent predictor of pCR. In addition, CAIX expression was associated with DFS and DSS (p = 0.005 and p = 0.012, respectively). Conclusions CAIX expression was a predictor of pCR and was associated with higher DFS and DSS in locally advanced breast cancer patients subjected to NAC.

scholarly journals CAIX is a predictor of pathological complete response and is associated with higher survival in locally advanced breast cancer submitted to neoadjuvant chemotherapy

2019 ◽  
Author(s):  
Wilson Eduardo Furlan Matos Alves ◽  
Murilo Bonatelli ◽  
Rozany Dufloth ◽  
Lígia Maria Kerr ◽  
Guilherme Freire Angotti Carrara ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Advanced Breast Cancer ◽  
Pathological Complete Response ◽  
Locally Advanced Breast Cancer ◽  
Locally Advanced ◽  
Complete Response ◽  
Advanced Breast ◽  
Metabolic Reprogramming ◽  
Caix Expression

Abstract Background Locally advanced breast cancer often undergoes neoadjuvant chemotherapy (NAC), which allows in vivo evaluation of the therapeutic response. The determination of the pathological complete response (pCR) is one way to evaluate the response to neoadjuvant chemotherapy. However, the rate of pCR differs significantly between molecular subtypes and the cause is not yet determined. Recently, the metabolic reprogramming of cancer cells and its implications for tumor growth and dissemination has gained increasing prominence and could contribute to a better understanding of NAC. Thus, this study proposed to evaluate the expression of metabolism-related proteins and its association with pCR and survival rates. Methods The expression of monocarboxylate transporters 1 and 4 (MCT1 and MCT4, respectively), cluster of differentiation 147 (CD147), glucose transporter-1 (GLUT1) and carbonic anhydrase IX (CAIX) was analyzed in 196 locally advanced breast cancer samples prior to NAC. The results were associated with clinical-pathological characteristics, occurrence of pCR, disease-free survival (DFS), disease-specific survival (DSS) and overall survival (OS). Results The occurrence of pCR was higher in the group of patients whith tumors expressing GLUT1 and CAIX than in the group without expression (27.8% versus 13.1%, p = 0.030 and 46.2% versus 13.5%, p = 0.007, respectively). Together with regional lymph nodes staging and mitotic staging, CAIX expression was considered an independent predictor of pCR. In addition, CAIX expression was associated with DFS and DSS (p = 0.005 and p = 0.012, respectively). Conclusions CAIX expression was a predictor of pCR and was associated with higher DFS and DSS in locally advanced breast cancer patients subjected to NAC.

Neoadjuvant chemotherapy in locally advanced breast cancer: Clinicopathological characteristics and correlation with pathological complete response.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e12658-e12658
Author(s):  
Priyanshu Choudhary ◽  
Ajay Gogia ◽  
Svs Deo ◽  
Sandeep Mathur ◽  
Dayanand Sharma
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Advanced Breast Cancer ◽  
Pathological Complete Response ◽  
Locally Advanced Breast Cancer ◽  
Locally Advanced ◽  
Complete Response ◽  
Advanced Breast ◽  
Stage Ii ◽  
Factors Affecting

e12658 Background: The data regarding incidence, response rates to neoadjuvant chemotherapy (NACT) and factors affecting pathological complete response (pCR) rate in locally advanced breast cancer (LABC) patients are lacking from India. Methods: This ambispective study was carried out at B.R.A., I.R.C.H, AIIMS, New Delhi, in between period of January 2013 to December 2019. We screened 1500 cases of breast cancer who presented to our institute and found 600 cases to be LABC,425 patients were started on NACT, 284 had undergone surgery and were included in our analysis. Results: The median age of diagnosis was 46 years (range 24-72years). Fifty four percent cases were postmenopausal, 54% had a left sided cancer,45 % right sided cancer,1 % had bilateral breast cancer. The median duration of symptoms was 5 months. The clinical stage according to AJCC staging system was Stage IIB – 11%(32), IIIA -21 % (58), IIIB- 60%(169) and IIIC- 8%(24) .Sixty five percent(186) cases presented with clinical skin involvement and 80% (228) patients has clinical node positivity.In our cohort 52% (148) cases were hormone positive (ER/PR positive), 42 %(119) cases were HER2/neu positive, 30%(84) were triple negative breast cancer (TNBC), 23 % (67) were positive for ER/PR and HER2/neu. Ninety percent of the cases were able to receive the planned neoadjuvant treatment before surgery. Post NACT 83% cases had a modified radical mastectomy (MRM) and 17% were able to undergo breast conserving surgery (BCS).Overall pCR was achieved in 59(21%) cases, 17% in hormone positive cases, 25% in HER2/neu positive cases (30% in cases receiving HER2/neu directed therapy vs 20% in cases who didn’t receive HER2 /neu directed therapy) and 27% in TNBC cases. During the study period 54 cases (19%) had relapsed,8 cases (3%) had a local relapse and a 46 cases (16%) had a systemic relapse. Grade ¾ toxicity occurred in 25 % cases, the most common were diarrhea, neutropenia, CINV, oral mucositis and thrombocytopenia and other rare toxicities (DVT, hand foot syndrome,myalgia). Febrile neutropenia was recorded in 2.5 % cases. There were 2 induction deaths. Stage II, absence of ER/PR expression showed statistically significant correlation with path CR rates. Conclusions: Locally advanced breast cancer constitutes around 40% cases at our institute. Post NACT pCR was achieved in 21% of cases, HER2/neu positive cases and TNBC showed higher pCR rates. The factors affecting pCR rate were absence of ER/PR expression and stage II disease.

Impact of pre-operative three different regimens on breast-conservation surgery (BCS) and pathological complete response rates (pCR) in locally advanced breast cancer (LABC) in Pakistani patients

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 10628-10628
Author(s):  
A. G. Alidina ◽  
A. Lal ◽  
S. Khan
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Pathological Complete Response ◽  
Locally Advanced Breast Cancer ◽  
Locally Advanced ◽  
Breast Conservation ◽  
Response Rates ◽  
Complete Response ◽  
Advanced Breast ◽  
Tac Chemotherapy

10628 Background: Locally advanced breast cancer accounts for 28% (n 350) of all breast cancer cases (1370 patients) treated at our Aga Khan University Hospital over the last 15 years. This is sharp comparison to the US data (only 3–6% of all cases). Methods: Patients with LABC who received surgery upfront were excluded. One hundred and seventy cases receiving PC were evaluated. Patients receiving TAC (taxotere, Adriamycin and cyclophosphamide)chemotherapy (n 60) were evaluated in a prospective Phase II study (2003- ongoing). These were then compared with FAC/AC or CMF regimens given from1998–2005, the data of which were extracted for Breast Cancer Tumor registry. Women were eligible if they were; histological confirmed invasive infiltrating carcinoma, clinical TNM: T3, T4, N2, N3, M0, as per AJCC (6th edition), PS 0–1, with adequate renal, liver and hematological functions. Patients were treated with regimens TAC containing T (75 mg/m2), A (50 mg/m2) and C (500 mg/m2) or FAC: F (500 mg/m2), A (50 mg/m2) and C (500 mg/m2) or A (60 mg/m2) C (600 mg/m2) and CMF: C (600 mg/m2), M (40 mg/m2) and F (600 mg/m2) q3wk 2 to 4 cycles. Type of surgery depended upon the response rates and the patients’ desire. Balance to complete a total of 4–6 cycles of chemotherapy was given in the adjuvant setting. Adjuvant hormone therapy was given for receptor positive cases. Results: Demographics, response rates, BCS and toxicities are reported in table. Conclusions: Locally advanced breast cancer is common in this region, owing to lack of screening. Preoperative TAC chemotherapy leads to impressively higher response rates, pathological complete response rates and probability of BCS, than when compared with FAC/AC chemotherapy or CMF chemotherapy, given in the same setting. Where as survival data of patients with TAC is not available, we feel that this will be superior to AC/FAC or CMF, given higher pathological complete response rates. [Table: see text] No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document